SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Long-Term Debt Issuances of -$4.4 million for Q2 2017, down 118.82% year-over-year from $23.6 million in Q2 2016, and down 200.0% quarter-over-quarter from $4.4 million in Q1 2017.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Long-Term Debt Issuances for 2 consecutive years, with -$4.4 million the latest figure, recorded in Q2 2017.
- In Q2 2017, Long-Term Debt Issuances fell 118.82% year-over-year to -$4.4 million; the TTM figure through Sep 2017 stood at -$22.1 million (down 193.66% YoY), while the FY2016 annual figure was $1.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances retreated to -$4.4 million in Q2 2017 per SLS's latest filing, from $4.4 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $23.6 million in Q2 2016 and bottomed at -$22.1 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | -4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Dec 31, 2016 | -8.64 Mn |
| Jun 30, 2016 | 23.64 Mn |